Global
About
Development milestones Mission&Vision Founder Research Achievement
Technical platform
Single domain antibody Five core technology platforms
Product pipeline
Business cooperation
Product Authorization Joint research and development External service
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Product pipeline

Progress and introduction
of main products

Product pipeline
Product layout focuses on advantages and products are rapidly promoted
Program
Disease field
Indication
Mode of administration
Clinical trial area
Preclinical
Drug Discovery
Cmc process development
Toxicological study
IND
Clinical Phase I
Clinical Phase II
Clinical Phase III
Commercialized interests
LQ036
Respiratory disease
EOS Asthma
Inhalation
Phase I clinical trail was completed ;Plan to License out
Global
EOS Asthma
Inhalation
SAD part completed, MAD dosing will be completed in the early Q4, 2023
Global
COPD
Inhalation
PD treatment approved on Sept 15th, 2023
Global
LQ036
More
LQ043
Respiratory disease
Non-EOS Asthma
Inhalation
SAD part completed
Global
COPD
Inhalation
Global
LQ043
More
LQ056
Respiratory disease
Lung Fibrosis
Inhalation
Global
LQ059
Respiratory disease
Cystic Fibrosis lung disease
Inhalation
Global
LQ041
Autoimmune disease
EGPA
Subcutaneous
Global
LQ041
More
LQ058
Immuno-Oncology
Tumour
Subcutaneous
Global
LQ061
Immuno-Oncology
Glioblastoma
Subcutaneous
Global